Project Inform Urges Government Action Following the Positive Results of Two PrEP Studies in Heterosexual Men and Women
July 13, 2011
San Francisco, CA -- Two new studies of pre-exposure prophylaxis (PrEP) in heterosexuals in Africa have demonstrated that the antiretroviral (ARV) drug tenofovir, taken by HIV-negative people, substantially reduces the number of new HIV infections.
"The success of these new studies -- when combined with similar results from a recent international PrEP study in men who have sex with men (MSM) and transgender females -- validate that ARVs have the power to substantially alter the course of the AIDS epidemic worldwide," said Dana Van Gorder, Project Inform's Executive Director. "As a result, Project Inform urges the U.S. government to work quickly with other partners in the philanthropic and research communities to determine how best to roll out both PrEP and treatment-as-prevention programs on a global scale."View Full Article
TDF2 Study of Pre-Exposure Prophylaxis (PrEP) Among Heterosexual Men and Women in Botswana: Key Facts
Open-Label Extension of iPrEx HIV Pre-Exposure Prophylaxis (PrEP) Study Begins at 11 Sites in Six Countries
Visit Project Inform's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)